LeonaBio, Inc. Restructuring and Related Cost, Cost Incurred to Date
LeonaBio, Inc. (LONA) had Restructuring and Related Cost, Cost Incurred to Date of $2.90 million as of 2024-12-31, per its 10-K filed 2026-03-31.
Financial Statements › Notes › Restructuring and Related Activities › Restructuring and Related Cost, Expected Cost
us-gaap:RestructuringAndRelatedCostCostIncurredToDate1 · last filed 2026-03-31
- 2024-12-31: Restructuring and Related Cost, Cost Incurred to Date $2.90M.
| Period end | Restructuring and Related Cost, Cost Incurred to Date |
|---|---|
| 2024-12-31 | $2.90M 10-K · filed 2026-03-31 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| Scilex Holding Co (SCLX) | United States | $0.042B | -0.14 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |
| EXOZYMES INC. (EXOZ) | United States | $0.058B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| MiNK Therapeutics, Inc. (INKT) | United States | $0.063B | -5.37 |